2-Amino-4,4-diphenyl-2-oxazoline | 132798-69-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Amino-4,4-diphenyl-2-oxazoline
• 英文别名: (4,4-diphenyl-5H-oxazol-2-yl)-amine；4,4-diphenyl-5H-1,3-oxazol-2-amine
• CAS: 132798-69-7
• 化学式: C₁₅H₁₄N₂O
• 分子量: 238.289
• InChiKey: ILWGZDIFHMTYDV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl isothiocyanate 、 2-Amino-4,4-diphenyl-2-oxazoline 、 丙酮 生成 [(2R,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-[(4,4-diphenyl-5H-1,3-oxazol-2-yl)carbamothioylamino]oxan-2-yl]methyl acetate
  参考文献：
  名称：

  MOTA, JOSE FUENTES;FERNANDEZ, JOSE M. CARCIA;MELLET, CARMEN ORTIZ;ADRIAN,+, J. CARBOHYDR. CHEM., 9,(1990) N, C. 837-851

  摘要：

  DOI：
• 作为产物：
  描述：

  2-iodo-1,1-diphenylethyl isocyanate 以 水 、 丙酮 为溶剂， 反应 0.66h， 生成 2-Amino-4,4-diphenyl-2-oxazoline
  参考文献：
  名称：

  碳水化合物和糖基氨基-恶唑啉的β-碘尿素衍生物的合成

  摘要：

  摘要N-（β-d-甘露糖基）-N'-（反式-2-碘代环己基）脲（3-7，N-（β-d-吡喃葡萄糖基）-N'-（2-碘-3,3）的合成-二甲基丁基）脲（8和9），N-（2-碘-1,1-二苯乙基）-N'-（β-d-吡喃并吡喃糖基）-脲（10），1,3,4,6-四- O-乙酰基-2-脱氧-2- [3-（反式-2-碘代环己基）脲基]-α-（11）和-β-d-吡喃葡萄糖（12），2-（2,3,4,6， -四-O-乙酰基-β-d-吡喃葡萄糖基氨基）-顺式-3a，4,5,6,7,7a-六氢苯并恶唑（15）和4,4-二苯基-2-（β-d-木吡喃糖基氨基）-报道了2-恶唑啉（16）。

  DOI：

  10.1016/0008-6215(92)84147-k

文献信息

• 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES
  申请人：Andreini Matteo

  公开号：US20090209529A1

  公开（公告）日：2009-08-20

  The present invention relates to a compounds of formula I wherein R 1 , R 1′ , R 2 , R 3 , R 4 , X, Ar, and m are as defined in the specification and claims and pharmaceutically active acid addition salts thereof. Compounds of the invention have Asp2 (β-secretase, BACE 1 or Memapsin-2) inhibitory activity and are useful for the treatment of diseases characterized by elevated β-amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.

  本发明涉及一种具有以下式I的化合物 其中R 1 ，R 1′ ，R 2 ，R 3 ，R 4 ，X，Ar和m如规范和索赔中定义，并且其药用活性酸盐。本发明的化合物具有Asp2（β-分泌酶，BACE 1或Memapsin-2）抑制活性，并且对于治疗由β-淀粉样蛋白水平升高或β-淀粉样蛋白沉积所特征的疾病，特别是阿尔茨海默病，是有用的。
• 2-Aminooxazolines as TAAR1 ligands
  申请人：Galley Guido

  公开号：US20080261920A1

  公开（公告）日：2008-10-23

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及化合物I的公式，其中X，Y，R1，R2和n如本文所定义，或其药学上适宜的酸加盐。本发明还涉及含有这种化合物的制药组合物和治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神障碍、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病。
• 2-AMINOOXAZOLINES AS TAAR1 LIGANDS
  申请人：Galley Guido

  公开号：US20100120864A1

  公开（公告）日：2010-05-13

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及式I的化合物，其中X，Y，R1，R2和n如本文所定义，或其药学适宜的酸加盐。本发明还涉及含有此类化合物的制药组合物，以及用于治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症，焦虑症，双相情感障碍，注意力缺陷多动障碍，应激相关障碍，精神疾病，精神分裂症，神经疾病，帕金森病，神经退行性疾病，阿尔茨海默病，癫痫，偏头痛，物质滥用和代谢性疾病，进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和吸收障碍，体温稳态障碍和功能障碍，睡眠和生物钟节律障碍以及心血管疾病。
• Fernandez, Jose M. Garcia; Mellet, Carmen Ortiz; Adrian, M. Angeles Pradera, Journal of Heterocyclic Chemistry, 1991, vol. 28, # 3, p. 777 - 780
  作者：Fernandez, Jose M. Garcia、Mellet, Carmen Ortiz、Adrian, M. Angeles Pradera、Mota, Jose Fuentes

  DOI：——

  日期：——
• MOTA, JOSE FUENTES;FERNANDEZ, JOSE M. CARCIA;MELLET, CARMEN ORTIZ;ADRIAN,+, J. CARBOHYDR. CHEM., 9,(1990) N, C. 837-851
  作者：MOTA, JOSE FUENTES、FERNANDEZ, JOSE M. CARCIA、MELLET, CARMEN ORTIZ、ADRIAN,+

  DOI：——

  日期：——